The Renin-Angiotensin System in Essential Hypertension

The recruitment status of this study is unknown because the information has not been verified recently.

Verified May 2007 by St George's, University of London. Recruitment status was Recruiting

First Received on August 31, 2005. Last Updated on May 10, 2007 History of Changes

Sponsor:	St George's, University of London
Information provided by:	St George's, University of London
ClinicalTrials.gov Identifier:	NCT00141583

Purpose

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Condition	Intervention
Hypertension	Drug: Enalapril 20 mg bd Drug: Candesartan 8 mg bd

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label
Official Title:	The Renin-Angiotensin System in Essential Hypertension

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Enalapril Enalapril maleate Enalaprilat CV 11974 Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by St George's, University of London:

Primary Outcome Measures:

Change in BP
Change in PRA and aldosterone

Estimated Enrollment:	11
Study Start Date:	April 2004
Estimated Study Completion Date:	October 2006

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Essential Hypertension
SBP 140-159 mmHg
DBP 90-99 mmHg

Exclusion Criteria:

Intolerance of or allergy to ACE Inhibitors or ARBS
Pregnant or Breastfeeding
Pre-menopausal women
Uncontrolled cardiac or renal failure
Diabetes mellitus

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00141583

Contacts

Contact: Timothy WR Doulton, BSc MRCP

+44 208 725 3176 ext -

tdoulton@sgul.ac.uk

Locations

United Kingdom
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL	Recruiting
London, United Kingdom, SW17 0RE
Contact: Timothy WR Doulton, BSc MRCP +44 208 725 3176 ext - tdoulton@sgul.ac.uk
Principal Investigator: Timothy WR Doulton, BSc MRCP

Sponsors and Collaborators

St George's, University of London

Investigators

Principal Investigator:

Timothy WR Doulton, BSc MRCP

SGUL

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00141583 History of Changes
Other Study ID Numbers:	LREC 01.87.10
Study First Received:	August 31, 2005
Last Updated:	May 10, 2007
Health Authority:	United Kingdom: Research Ethics Committee

Keywords provided by St George's, University of London:

Renin-angiotensin system
ACE Inhibitor
Angiotensin Receptor Blocker

Additional relevant MeSH terms:

Hypertension
Vascular Diseases
Cardiovascular Diseases
Enalapril
Candesartan
Candesartan cilexetil
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors

Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Angiotensin II Type 1 Receptor Blockers

ClinicalTrials.gov processed this record on February 09, 2012